Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference
June 04 2019 - 4:05PM
Business Wire
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology
company developing next-generation neuromodulators for use in
treating aesthetic and therapeutic conditions, today announced that
the company will participate in the Goldman Sachs 40th Annual
Global Healthcare Conference in Rancho Palos Verdes, CA.
President and Chief Executive Officer, Dan Browne, is scheduled
to present on Tuesday, June 11 at 3:20 p.m. PT.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company's
website at www.revance.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 30
days.
About Revance Therapeutics, Inc.
Revance Therapeutics is a biotechnology company focused on
developing transformative neuromodulators to address a broad
spectrum of aesthetic and therapeutic conditions. Revance’s lead
product candidate, DaxibotulinumtoxinA for Injection (DAXI),
utilizes a unique proprietary peptide excipient technology combined
with highly purified botulinum toxin type A to produce a novel,
long-acting neuromodulator set to enter a $4.5 billion global
market. In aesthetics, Revance successfully completed its Phase 3
program for DAXI in glabellar (frown) lines and is currently
pursuing U.S. regulatory approval in 2020, while also running two
separate Phase 2 studies in forehead lines and lateral canthal
lines (crow’s feet). In therapeutics, DAXI is being studied in
three indications, including a Phase 3 trial in cervical dystonia,
a Phase 2 trial in adult upper limb spasticity, and a Phase 2 trial
in plantar fasciitis, with plans to also study migraine. Beyond
DAXI, Revance also has begun development of a biosimilar to BOTOX®,
which would compete in the existing short-acting neuromodulator
marketplace. More information on Revance may be found at
www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
BOTOX® is a registered trademark of Allergan, Inc.
Source: Revance Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190604005530/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorGilmartin Group, LLC.:Laurence
Watts, 619-916-7620laurence@gilmartinir.comMEDIAGeneral
Media:Y&R:Jenifer Slaw347-971-0906jenifer.slaw@YR.comorTrade
Media:Nadine Tosk, 504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Apr 2024 to May 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From May 2023 to May 2024